---
layout: minimal-medicine
title: Sebelipase Alfa
---

# Sebelipase Alfa
### Generic Name
Sebelipase Alfa

### Usage
Sebelipase alfa is a medication used to treat lysosomal acid lipase (LAL) deficiency.  LAL deficiency is a rare genetic disorder where the body lacks or has insufficient amounts of the enzyme lysosomal acid lipase. This enzyme is crucial for breaking down fats (cholesteryl esters and triglycerides) within the body's cells.  A deficiency leads to a buildup of these fats in various organs, including the liver, spleen, and other tissues.  This accumulation can cause significant health problems, potentially impacting liver function, leading to cardiovascular issues, and affecting overall growth and development. Sebelipase alfa acts as a replacement for the missing or deficient enzyme, helping to break down the accumulated fats and alleviate symptoms associated with LAL deficiency.  The treatment aims to manage the progression of the disease and improve patients' quality of life.

### Dosage

**Adult Dosage:**

For lysosomal acid lipase deficiency, the typical dosage is 1 mg/kg administered intravenously (IV) over a period of 2 hours every other week.  In cases of rapidly progressing disease (significant deterioration within 6 months), an initial dose of 1 mg/kg IV over 2 hours once weekly may be used. If a sufficient clinical response is not seen, the dose may be increased to 3 mg/kg IV over more than 2 hours once weekly.

**Pediatric Dosage:**

For children aged 1 month to 18 years, the recommended dosage is 1 mg/kg administered intravenously (IV) over 2 hours every other week.  The safety and efficacy of sebelipase alfa have not been established for children younger than 1 month old.


**Dosage Adjustments:**  The manufacturer's labeling does not provide specific dosage adjustments for patients with hepatic (liver) or renal (kidney) impairment.  However, caution is advised when using sebelipase alfa in these patient populations.  If hypersensitivity reactions occur, dosage adjustments may be needed under the guidance of a healthcare professional.  Mild to moderate reactions might warrant interrupting the infusion and then resuming at a slower rate.  Severe reactions or anaphylaxis necessitate immediate discontinuation of the infusion.

### Side Effects

**Common Side Effects (occurring in more than 10% of patients):**

* Headache
* Urticaria (hives) and rash
* Nasopharyngitis (inflammation of the nose and throat), rhinitis (inflammation of the nasal lining), cough, and oropharyngeal pain (pain in the throat)
* Anemia
* Diarrhea and vomiting
* Fever

**Less Common Side Effects (occurring in 1-10% of patients):**

* Constipation
* Nausea
* Asthenia (weakness or fatigue)

**Rare Side Effects (occurring in less than 1% of patients):**

* Chest discomfort
* Hyperlipidemia (high levels of fats in the blood)
* Tachycardia (rapid heart rate)
* Hypotonia (low muscle tone)


**Important Note:**  This list is not exhaustive.  Any new or worsening symptoms should be reported to a healthcare provider immediately.


### How it Works

Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. It works by replacing the deficient or missing enzyme in patients with LAL deficiency.  The medication is administered intravenously and then enters the cells through binding to cell-surface receptors.  Once inside the lysosomes (organelles within cells responsible for waste breakdown), it catalyzes the breakdown of cholesteryl esters and triglycerides into their simpler components (free cholesterol, glycerol, and free fatty acids). This process reduces the accumulation of these fats in various organs and tissues, addressing the underlying cause of the disease.

### Precautions

* **Contraindications:** Sebelipase alfa is contraindicated in patients with a life-threatening hypersensitivity to the medication or its components.
* **Increased Risk:** Patients receiving sebelipase alfa have an increased risk of developing hypersensitivity reactions (including anaphylaxis) and formation of anti-drug antibodies.
* **Use with Caution:** Exercise caution when administering sebelipase alfa to patients with hypersensitivity to egg and egg products (as it is produced using an egg-based system), pregnant or breastfeeding women, and those with renal or hepatic impairment.  Close monitoring is crucial in these populations.

### FAQs

* **Q: How is sebelipase alfa administered?** A: It's administered intravenously as a slow infusion, usually over 2 hours.
* **Q: How long does treatment last?** A: Treatment with sebelipase alfa is generally long-term, and the duration depends on the individual patient's response and clinical condition.  This is determined by a healthcare professional.
* **Q: What should I do if I experience side effects?** A: Report any side effects, especially severe ones, to your doctor immediately.
* **Q: How should sebelipase alfa be stored?** A: Follow the storage instructions provided by your pharmacist or healthcare provider.  Typically, it requires refrigeration.
* **Q: Are there any interactions with other medications?** A: While not extensively documented, interactions are possible.  Always inform your doctor of all medications you are taking, including over-the-counter drugs and supplements.
* **Q: Is sebelipase alfa safe for pregnant or breastfeeding women?** A: The safety of sebelipase alfa during pregnancy and lactation is not fully established.  Use should be carefully considered and only under the close supervision of a healthcare provider.


**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional for diagnosis and treatment of any medical condition.  The information provided here reflects currently available data and may be subject to change as further research is conducted.
